To Evaluate the Efficacy of a Nutraceutical in Reducing Cardiovascular Risk in Healthy Subjects

Subjects who meet the selection criteria will make a total of two visits to the research laboratory and will carry out the tests established in the protocol. Subsequently, a statistical analysis will be performed with the variables measured in the study to obtain results.

Inclusion criteria

• Subjects of both sexes (men or women) between 30 and 75 years of age, Caucasian.
• Present body mass index between 20 and 32 Kg / m2.
• Presenting fasting serum LDL-cholesterol levels equal to or greater than 110 mg / dL or total serum cholesterol equal to or greater than 180 mg / dL.
• Volunteers capable of understanding the clinical study and willing to grant written informed consent and to comply with study procedures and requirements.

Exclusion criteria

• Thyroid dysfunction, infections, or with any type of chronic disease (eg, autoimmune, inflammatory).
• Subjects who have suffered an ischemic-vascular event in the last months.
• Subjects in medication and / or nutraceutical treatment for hypertension, diabetes or hyperlipidemia (ex: statins).
• Subjects in treatment with drugs that due to their narrow therapeutic margin require monitoring of their plasma levels (digoxin, acenocoumarol, warfarin, etc ...).
• Subjects in treatment that affects body weight or appetite.
• History of allergic hypersensitivity or poor tolerance to any component of the products under study.
• Subjects who are carrying out or intend to carry out any type of diet, low-calorie or not, during the study.
• Subjects who have donated a minimum of 0.5L of blood in the last month Vegetarian subjects.
• Subjects who have ingested omega 3 and / or 6 supplements in the last three months, (eg, fish oil, evening primrose oil, krill oil, or algae oil).
• Subjects under treatment with niacin or fibrates.
• Those subjects with alcohol abuse, or with excessive alcohol consumption (> 3 glasses of wine or beer / day) were excluded.
• Patients undergoing major surgery in the last 3 months.
• Smoking subjects or not, but in any case who have changed their nicotinic habits during their participation in the study.
• Participation in another clinical trial in the three months prior to the study.
• Lack of will or inability to comply with clinical trial procedures.
• Subjects whose condition did not make them eligible for the study according to the researcher's criteria.